Vaxcyte’s 24-Valent Pneumococcal Vaccine Shows Best-In-Class Potential

Small Biotech Hopes To Compete In Big Pharma-Dominated Market

 
• By Joseph Haas
Vaccine syringe
Vaxcyte's proof-of-concept data for its PCV candidate has company, investors excited • Source: Shutterstock

More from Clinical Trials

More from R&D